




# PHARMACEUTICAL 2021

Aclaris Therapeutics Inc.  
Rank 271 of 402





# PHARMACEUTICAL 2021

Aclaris Therapeutics Inc.  
Rank 271 of 402



The relative strengths and weaknesses of Aclaris Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aclaris Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 12% points. The greatest weakness of Aclaris Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 26%, being 21% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	57,493
Cost of Goods Sold	5,133
Intangible Assets	7,123
Liabilities, Current	14,874
Liabilities, Non-Current	3,179
Other Assets	4,514
Other Compr. Net Income	-28
Other Expenses	-182
Other Liabilities	15,081
Other Net Income	-285
Other Revenues	6,482
Property and Equipment	1,654
Research and Development	31,731
Selling, General and Administrative Expense	20,530

Output Variable	Value in 1000 USD
Assets	70,784
Liabilities	33,134
Expenses	57,212
Revenues	6,482
Stockholders Equity	37,650
Net Income	-51,015
Comprehensive Net Income	-51,029
Economic Capital Ratio	26%